The prolyl hydroxylase inhibitor molidustat fails to restore erythropoietin production in the fibrotic kidney

Acta Physiol (Oxf). 2022 Aug;235(4):e13858. doi: 10.1111/apha.13858. Epub 2022 Jul 6.

Authors

Gunnar Schley¹, Andrea Hartner²

Affiliations

¹ Department of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg (FAU), University Hospital Erlangen, Erlangen, Germany.
² Department of Pediatrics and Adolescent Medicine, Friedrich-Alexander University Erlangen-Nürnberg (FAU), University Hospital Erlangen, Erlangen, Germany.

PMID: 35768895
DOI: 10.1111/apha.13858

No abstract available

Publication types

Editorial
Comment

MeSH terms

Erythropoietin*
Humans
Hypoxia-Inducible Factor-Proline Dioxygenases
Kidney
Prolyl-Hydroxylase Inhibitors*
Pyrazoles
Renal Insufficiency, Chronic*
Triazoles / pharmacology

Substances

Prolyl-Hydroxylase Inhibitors
Pyrazoles
Triazoles
Erythropoietin
molidustat
Hypoxia-Inducible Factor-Proline Dioxygenases